Intensity Therapeutics (INTS) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $3.38, -1.17% vs the prior close of $3.42.
- Volume 8.30K shares, 0.3x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
INTS dips 1.2% to $3.38. Closed at $3.38, -1.17% vs the prior close of $3.42. Day range $3.35–$3.55, opened at $3.35.
INTS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — INTS dips 1.2% to $3.38
- Closed at $3.38, -1.17% vs the prior close of $3.42. Day range $3.35–$3.55, opened at $3.35.
- Volume was 8.30K shares, 0.3x its 50-day average of 27.62K — lighter than usual.
- Price is -15.0% vs its 50-day average ($3.98) and -39.7% vs its 200-day average ($5.61).
- 52-week range $3.10–$43.50; today's close sits at 1% of that range, 92.2% below the 52-week high.
Oct 14, 2026 — INTS slides 3.7% to $3.42
- Closed at $3.42, -3.66% vs the prior close of $3.55. Day range $3.29–$3.58, opened at $3.56.
- Volume was 25.90K shares, 0.9x its 50-day average of 27.76K.
- Price is -14.4% vs its 50-day average ($3.99) and -39.3% vs its 200-day average ($5.63).
- 52-week range $3.10–$43.50; today's close sits at 1% of that range, 92.1% below the 52-week high.
Oct 13, 2026 — INTS jumps 7.3% to $3.55 on 4.8x normal volume
- Closed at $3.55, +7.25% vs the prior close of $3.31. Day range $3.10–$4.04, opened at $3.20.
- Volume was 123.70K shares, 4.8x its 50-day average of 25.53K — unusually heavy trading.
- Price is -11.4% vs its 50-day average ($4.01) and -37.3% vs its 200-day average ($5.67).
- 52-week range $3.10–$43.50; today's close sits at 1% of that range, 91.8% below the 52-week high.
Oct 12, 2026 — INTS slides 8.8% to $3.31, 3 down days in a row
- Closed at $3.31, -8.82% vs the prior close of $3.63. Day range $3.14–$3.70, opened at $3.70.
- Volume was 42.00K shares, 1.6x its 50-day average of 26.25K.
- Price is -17.7% vs its 50-day average ($4.02) and -41.9% vs its 200-day average ($5.70).
- 52-week range $3.14–$43.50; today's close sits at 0% of that range, 92.4% below the 52-week high.
- That makes 3 straight losses.
Oct 9, 2026 — INTS dips 1.4% to $3.63
- Closed at $3.63, -1.36% vs the prior close of $3.68. Day range $3.55–$3.75, opened at $3.75.
- Volume was 16.70K shares, 0.6x its 50-day average of 26.80K.
- Price is -10.1% vs its 50-day average ($4.04) and -36.7% vs its 200-day average ($5.74).
- 52-week range $3.21–$43.50; today's close sits at 1% of that range, 91.7% below the 52-week high.
Oct 8, 2026 — INTS slides 3.2% to $3.68
- Closed at $3.68, -3.16% vs the prior close of $3.80. Day range $3.58–$3.80, opened at $3.76.
- Volume was 19.20K shares, 0.7x its 50-day average of 26.85K.
- Price is -9.1% vs its 50-day average ($4.05) and -36.2% vs its 200-day average ($5.77).
- 52-week range $3.21–$43.50; today's close sits at 1% of that range, 91.5% below the 52-week high.
Oct 7, 2026 — INTS jumps 7.0% to $3.80, 4 up days in a row
- Closed at $3.80, +7.04% vs the prior close of $3.55. Day range $3.46–$3.87, opened at $3.47.
- Volume was 17.20K shares, 0.6x its 50-day average of 27.11K.
- Price is -6.4% vs its 50-day average ($4.06) and -34.5% vs its 200-day average ($5.80).
- 52-week range $3.21–$43.50; today's close sits at 1% of that range, 91.3% below the 52-week high.
- That makes 4 straight gains.
Oct 6, 2026 — INTS rises 2.9% to $3.55, 3 up days in a row
- Closed at $3.55, +2.90% vs the prior close of $3.45. Day range $3.34–$3.67, opened at $3.34.
- Volume was 7.50K shares, 0.3x its 50-day average of 27.18K — lighter than usual.
- Price is -12.9% vs its 50-day average ($4.08) and -39.2% vs its 200-day average ($5.84).
- 52-week range $3.21–$43.50; today's close sits at 1% of that range, 91.8% below the 52-week high.
- That makes 3 straight gains.
Oct 5, 2026 — INTS ends flat (+0.3%) to $3.45
- Closed at $3.45, +0.29% vs the prior close of $3.44. Day range $3.45–$3.75, opened at $3.45.
- Volume was 28.80K shares, 1.1x its 50-day average of 26.67K.
- Price is -15.8% vs its 50-day average ($4.10) and -41.2% vs its 200-day average ($5.87).
- 52-week range $3.21–$43.50; today's close sits at 1% of that range, 92.1% below the 52-week high.
Oct 2, 2026 — INTS jumps 7.2% to $3.44
- Closed at $3.44, +7.17% vs the prior close of $3.21. Day range $3.21–$3.45, opened at $3.27.
- Volume was 15.40K shares, 0.6x its 50-day average of 26.52K — lighter than usual.
- Price is -16.4% vs its 50-day average ($4.12) and -41.8% vs its 200-day average ($5.91).
- 52-week range $3.21–$43.50; today's close sits at 1% of that range, 92.1% below the 52-week high.
INTS latest news & SEC filings
Every SEC filing by or about INTS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$3.01M (prior year -$2.54M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.11 (prior year -$3.36) (loss narrowed vs Jun 30, 2025)
Jul 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 8, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Things to know before you trade INTS
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 27, 2026, Mar 5, 2026. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.87% (largest 8.8%). That is a volatile stock.
- Liquidity: about 25.02K shares (≈$84.57K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $3.38 vs a range of $3.10–$43.50 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:25 on Feb 19, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Aug 11, 2026; 10-Q Aug 11, 2026; 8-K Jun 16, 2026.
- Share count: 3.26M shares outstanding (Aug 7, 2026), -93.1% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
INTS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 3.35 | 3.55 | 3.35 | 3.38 | 8.30K |
| Oct 14, 2026 | 3.56 | 3.58 | 3.29 | 3.42 | 25.90K |
| Oct 13, 2026 | 3.20 | 4.04 | 3.10 | 3.55 | 123.70K |
| Oct 12, 2026 | 3.70 | 3.70 | 3.14 | 3.31 | 42.00K |
| Oct 9, 2026 | 3.75 | 3.75 | 3.55 | 3.63 | 16.70K |
| Oct 8, 2026 | 3.76 | 3.80 | 3.58 | 3.68 | 19.20K |
| Oct 7, 2026 | 3.47 | 3.87 | 3.46 | 3.80 | 17.20K |
| Oct 6, 2026 | 3.34 | 3.67 | 3.34 | 3.55 | 7.50K |
| Oct 5, 2026 | 3.45 | 3.75 | 3.45 | 3.45 | 28.80K |
| Oct 2, 2026 | 3.27 | 3.45 | 3.21 | 3.44 | 15.40K |
| Oct 1, 2026 | 3.36 | 3.56 | 3.21 | 3.21 | 15.30K |
| Sep 30, 2026 | 3.40 | 3.46 | 3.28 | 3.37 | 20.90K |
| Sep 29, 2026 | 3.70 | 3.70 | 3.27 | 3.42 | 34.00K |
| Sep 28, 2026 | 3.90 | 3.90 | 3.63 | 3.65 | 36.20K |
| Sep 25, 2026 | 4.10 | 4.10 | 3.80 | 3.80 | 8.40K |
| Sep 24, 2026 | 4.18 | 4.18 | 3.89 | 3.89 | 10.60K |
| Sep 23, 2026 | 3.98 | 4.10 | 3.98 | 4.10 | 4.10K |
| Sep 22, 2026 | 4.01 | 4.11 | 3.89 | 4.01 | 14.70K |
| Sep 21, 2026 | 4.24 | 4.30 | 4.02 | 4.02 | 6.40K |
| Sep 18, 2026 | 3.79 | 4.29 | 3.79 | 4.11 | 45.10K |
About Intensity Therapeutics
Intensity Therapeutics (INTS) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SHELTON, CT. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1567264.
INTS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Lewis H Bender | President and CEO | Jul 20, 2026 |
| Thomas I H Dubin | Director | Jul 20, 2026 |
| Daniel Donovan | Director | Jul 20, 2026 |
| Mark A Goldberg | Director | Jul 20, 2026 |
| Emer Leahy | Director | Jul 20, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Lewis H Bender | President and CEO | Jul 20, 2026 |
| Joseph Talamo | Chief Financial Officer | Jul 20, 2026 |
| John M Wesolowski | Principal Accounting Officer | Jul 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
INTS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-11.61M | -8.56 | $-9.23M |
| Dec 31, 2024 | — | $-16.27M | -29.24 | $-15.22M |
| Dec 31, 2023 | — | $-10.54M | -1.38 | $-7.21M |
| Dec 31, 2022 | — | $-7.58M | -2.22 | $-5.48M |
Latest balance sheet: total assets $11.52M, total liabilities $2.31M, cash $9.53M (as of Jun 30, 2026).
INTS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $4.20 |
| May 7, 2026 | 8-K Item 2.02 (results) | $5.11 |
| Mar 27, 2026 | 8-K Item 2.02 (results) | $6.03 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $7.72 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $12.12 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $6.30 |
| May 13, 2025 | 8-K Item 2.02 (results) | $12.95 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $58.12 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $77.50 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 14, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on INTS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.